Latest Oncology News

Mirvetuximab Soravtansine Displays Promising Efficacy in Platinum-Resistant Ovarian Cancer

July 2nd 2022

Kyle Doherty

Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options.

ALRN-6924 Halts Development in P53-Mutant NSCLC, Advances in P53-Mutant Breast Cancer

July 1st 2022

Caroline Seymour

Drug manufacturer Aileron plans to stop further enrollment into a phase 1b trial (NCT04022876) after the chemoprotective agent ALRN-6924 missed its composite primary end point for patients with advanced p53-mutant non–small cell lung cancer.

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC

July 1st 2022

Brittany Lovely

Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

Chris Ryan

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Orphan Drug Designation to Evorpacept for AML

July 1st 2022

Caroline Seymour

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

Latest Oncology Videos

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

Improving Outcomes in Patients With DLBCL

Dr. Park on the Role of Cemiplimab in Advanced Basal Cell Carcinoma

Mechanism of Action of Ruxolitinib

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

Dr. Yoon on Updated Data on Tislelizumab Plus Chemotherapy in ESCC

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

Dr. Monk on the Need for Molecular Testing in Ovarian Cancer

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

A Focus on Frontline Treatment in Patients With DLBCL

Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

Making a Diagnosis of Immune Thrombocytopenia

Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

Managing Patients with Essential Thrombocythemia

Myeloproliferative Neoplasms: Essential Thrombocythemia

MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

Early-Stage HCC: Role of Adjuvant Therapy

Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

Future Directions in the Management of HER2+ Breast Cancer

Patient Profile 1: Resection for Early/Intermediate Stage HCC

All Oncology News

Lung Cancer Pioneer Paves Path for Future Innovation

September 24th 2021

Meir Rinde

The achievements of Roman Perez-Soler, MD, include studies of anti-EGFR therapies and topoisomerase inhibitors, extensive research on liposomal delivery systems, and early work on patient-derived xenografts in mice.

Identifying ILD: Symptomology and Work-Up

September 24th 2021

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24th 2021

Jessica Hergert

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

An Overview of Interstitial Lung Disease

September 24th 2021

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics

September 24th 2021

Timothy Schmidt, MD, University of Wisconsin

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.

Second-Line Treatment Approaches for Advanced HCC

September 24th 2021

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

September 24th 2021

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23rd 2021

Douglas W. Sborov, MD, MS

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

September 23rd 2021

Peter Riedell, MD

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

September 23rd 2021

OncLive Staff

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Fixed-Dose Eniluracil Under Investigation in Advanced Refractory Gastrointestinal Cancers

September 23rd 2021

Gina Mauro

Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.

Durvalumab Plus Olaparib or Cediranib Leads to Disease Stabilization in Leiomyosarcoma

September 23rd 2021

Maggie Tibbitt

Albiruni Ryan Abdul Razak, discusses the rationale for examining durvalumab with either olaparib or cediranib in patients with LMS, key data reported with this approach, and next steps for the phase 2 DAPPER study.

Cedars-Sinai Researchers Develop New Melanoma Staging System

September 23rd 2021

Cedars-Sinai Cancer researchers have created a new system for classifying melanoma when the disease has spread to the lymph nodes.

Challenges Identified With Low Clinical Trial Accrual for AYA Patients With Sarcoma

September 23rd 2021

Gina Mauro

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

See All News